American Journal of Kidney Diseases
Volume 50, Issue 3 , Pages 358-361 , September 2007

Dialysis Facility Ownership and Epoetin Dosing in Hemodialysis Patients: A View From Europe

  • Iain C. Macdougall, MD

      Affiliations

    • Corresponding Author InformationAddress correspondence to Iain C. Macdougall, MD, Renal Unit, King’s College Hospital, London SE5 9RS United Kingdom.

References 

  1. Thamer M, Zhang Y, Kaufman J, Cotter D, Dong F, Hernan MA. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA. 2007;297:1667–1674
  2. Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004;44:94–111
  3. Kaufman JS, Reda DJ, Fye CL, et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis (Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients). N Engl J Med. 1998;339:578–583
  4. Covic A, Locatelli F, Macdougall IC, Wiecek A. Achievement of EBPG targets in Eastern and Western Europe: ORAMA preliminary results. In: World Congress of Nephrology 2007 Book of Abstracts. 2007;p. 293;Rio de Janeiro, Brazil, April 21-25, (abstr)
  5. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;346:469–475
  6. Gershon SK, Luksenburg H, Cote TR, Braun MM. Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med. 2002;346:1584–1586
  7. The Renal Association. UK Renal Registry: The Eighth Annual Report. 2005;Bristol, United Kingdom, December
  8. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;335:2085–2098
  9. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;335:2071–2084
  10. Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis. 2004;44:866–876
  11. Besarab A, Bolton WK, Brown JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–590
  12. Macdougall IC, Roberts DE, Coles GA, Williams JD. Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin Pharmacokinet. 1991;20:99–113

PII: S0272-6386(07)01039-6

doi: 10.1053/j.ajkd.2007.07.010

American Journal of Kidney Diseases
Volume 50, Issue 3 , Pages 358-361 , September 2007

Article Tools

* Image Usage & Resolution